Levodopa/carbidopa intestinal gel infusion in advanced Parkinson's disease: A 7-year experience

European Journal of Neurology

Volumn 21, Issue 2, 2014, Pages 312-318

  Zibetti, M ^a   Merola, A ^a   Artusi, C A ^a   Rizzi, L ^a   Angrisano, S ^a   Reggio, D ^b   De Angelis, C ^b   Rizzone, M ^a   Lopiano, L ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b Division of Endoscopy   (Italy)

Author keywords

Duodopa; Levodopa carbidopa intestinal gel infusion; Long term follow up; Parkinson's disease

Indexed keywords

AMANTADINE; ANTIBIOTIC AGENT; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT;

ACUTE PSYCHOSIS; ADULT; AGED; ANOREXIA; ANTIBIOTIC THERAPY; ARTICLE; BODY WEIGHT DISORDER; CONTINUOUS INFUSION; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DISEASE DURATION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFECT; DUODENUM PERFORATION; DYSARTHRIA; DYSKINESIA; DYSPHAGIA; DYSTONIA; FEMALE; FOLLOW UP; GAIT DISORDER; GASTROSTOMY; GEL; HUMAN; INFUSION PUMP; INTESTINE VOLVULUS; LONG TERM CARE; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL DEVICE COMPLICATION; MIDDLE AGED; MONOTHERAPY; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; NASOGASTRIC TUBE; NAUSEA; NEUROPATHY; OPTIMAL DRUG DOSE; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PERCUTANEOUS ENDOSCOPIC GASTROSTOMY; PERITONITIS; PHLEGMON; PNEUMOPERITONEUM; POLYNEUROPATHY; PRIORITY JOURNAL; QUALITY OF LIFE; SEMI STRUCTURED INTERVIEW; SLEEP DISORDER; STOMACH ULCER; TREATMENT DURATION; UNIFIED PARKINSON DISEASE RATING SCALE; VERY ELDERLY;

DUODOPA; LEVODOPA/CARBIDOPA INTESTINAL GEL INFUSION; LONG-TERM FOLLOW-UP; PARKINSON'S DISEASE;

AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; CARBIDOPA; DRUG COMBINATIONS; FEMALE; GELS; HUMANS; INFUSIONS, PARENTERAL; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; TREATMENT OUTCOME;

EID: 84892477877     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/ene.12309     Document Type: Article

References (26)

1. Lees AJ, Hardy J, Revesz T. Parkinson's disease. Lancet 2009; 373: 2055-2066.
2. Coelho M, Ferreira JJ. Late-stage Parkinson disease. Nat Rev Neurol 2012; 8: 435-442.
3. Nyholm D, Lennernas H, Gomes-Trolin C, Aquilonius SM. Levodopa pharmacokinetics and motor performance during activities of daily living in patients with Parkinson's disease on individual drug combinations. Clin Neuropharmacol 2002; 25: 89-96.
4. Nyholm D, Askmark H, Gomes-Trolin C, et al. Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets. Clin Neuropharmacol 2003; 26: 156-163.
5. Clarke CE, Worth P, Grosset D, Stewart D. Systematic review of apomorphine infusion, levodopa infusion and deep brain stimulation in advanced Parkinson's disease. Parkinsonism Relat Disord 2009; 15: 728-741.
6. Nyholm D, Nilsson Remahl AI, Dizdar N, et al. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology 2005; 64: 216-223.
7. ® treatment for advanced Parkinson's disease: a review of efficacy and safety. Parkinsonism Relat Disord 2012; 18: 916-929.
8. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181-184.
9. Wenning GK, Ben-Shlomo Y, Hughes A, Daniel SE, Lees A, Quinn NP. What clinical features are most useful to distinguish definite multiple system atrophy from Parkinson's disease? J Neurol Neurosurg Psychiatry 2000; 68: 434-440.
10. Emre M. Dementia associated with Parkinson's disease. Lancet Neurol 2003; 2: 229-237.
11. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 2010; 25: 2649-2653.
12. Devos D; French Duodopa Study Group. Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease. Mov Disord 2009; 24: 993-1000.
13. Zibetti M, Merola A, Ricchi V, et al. Long-term duodenal levodopa infusion in Parkinson's disease: a 3-year motor and cognitive follow-up study. J Neurol 2013; 260: 105-114.
14. Nyholm D, Lewander T, Johansson A, LeWitt P, Lundqvist C, Aquilonius S-M. Enteral levodopa infusion in advanced Parkinson's disease - 216 patient-years of experience. Clin Neuropharmacol 2008; 31: 63-73.
15. Antonini A, Odin P, Lopiano L, et al. Effect and safety of duodenal levodopa infusion in advanced Parkinson's disease: a retrospective multicenter outcome assessment in patient routine care. J Neural Transm 2013; 11: 1553-1558.
16. Nyholm D, Klangemo K, Johansson A. Levodopa/carbidopa intestinal gel infusion long-term therapy in advanced Parkinson's disease. Eur J Neurol 2012; 19: 1079-1085.
17. Chapuis S, Ouchchane L, Metz O, Gerbaud L, Durif F. Impact of the motor complications of Parkinson's disease on the quality of life. Mov Disord 2005; 20: 224-230.
18. Shulman LM, Gruber-Baldini AL, Anderson KE, Fishman PS, Reich SG, Weiner WJ. The clinically important difference on the unified Parkinson's disease rating scale. Arch Neurol 2010; 67: 64-70.
19. Honig H, Antonini A, Martinez-Martin P, et al. Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. Mov Disord 2009; 24: 1468-1474.
20. Nyholm D, Jansson R, Willows T, Remahl I. Long-term 24-hour duodenal infusion of levodopa: outcome and dose requirements. Neurology 2005; 65: 1506-1507.
21. Foltynie T, Magee C, James C, Webster GJ, Lees AJ, Limousin P. Impact of duodopa on quality of life in advanced Parkinson's disease: a UK case series. Parkinsons Dis 2013; 2013: 362908.
22. Klostermann F, Jugel C, Bömelburg M, Marzinzik F, Ebersbach G, Müller T. Severe gastrointestinal complications in patients with levodopa/carbidopa intestinal gel infusion. Mov Disord 2012; 27: 1704-1705.
23. Manca D, Cossu G, Murgia D, et al. Reversible encephalopathy and axonal neuropathy in Parkinson's disease during duodopa therapy. Mov Disord 2009; 24: 2293-2294.
24. Urban PP, Wellach I, Faiss S, et al. Subacute axonal neuropathy in Parkinson's disease with cobalamin and vitamin B6 deficiency under duodopa therapy. Mov Disord 2010; 25: 1748-1752.
25. Klostermann F, Jugel C, Müller T, Marzinzik F. Malnutritional neuropathy under intestinal levodopa infusion. J Neural Transm 2012; 119: 369-372.
26. Merola A, Zibetti M, Rizzone MG, et al. Prospective assessment of peripheral neuropathy in Duodopa-treated parkinsonian patients. Acta Neurol Scand 2014. 129: e1-e5.